3.
Clinical factors associated with EGFRvIII nuclear translocation level by univariate analysis
| Clinical factors | EGFRvIII unclear translocation (%) | P | |
| Low level (<7%) | High level (≥7%) | ||
| EGFRvIII, epidermal growth factor receptor variant III; KPS, Karnofsky performance scale; MGMT, O6-methylguanine-DNA
methyltransferase; IDH, isocitrate dehydrogenase. | |||
| Gender | 0.484 | ||
| Male | 62.2 (89/143) | 37.8 (54/143) | |
| Female | 57.7 (56/97) | 42.3 (41/97) | |
| Age (year) | 0.030 | ||
| <50 | 64.3 (117/182) | 35.7 (65/182) | |
| ≥50 | 48.3 (28/58) | 51.7 (30/58) | |
| Tumor size (cm) | 0.356 | ||
| <6 | 63.3 (76/120) | 36.7 (44/120) | |
| ≥6 | 57.5 (69/120) | 42.5 (51/120) | |
| KPS score | 0.019 | ||
| ≤80 | 51.9 (54/104) | 48.1 (50/104) | |
| >80 | 66.9 (91/136) | 33.1 (45/136) | |
| Tumor grade | 0.045 | ||
| II | 69.0 (58/84) | 31.0 (26/84) | |
| III+IV | 55.8 (87/156) | 44.2 (69/156) | |
| MGMT methylation | 0.141 | ||
| Yes | 66.0 (70/106) | 34.0 (36/106) | |
| No | 53.3 (24/45) | 46.7 (21/45) | |
| IDH mutation | 0.038 | ||
| Yes | 65.2 (103/158) | 34.8 (55/158) | |
| No | 51.2 (41/80) | 48.8 (39/80) | |
| 1p/19q codeletion | 0.709 | ||
| Yes | 58.8 (50/85) | 41.2 (35/85) | |
| No | 61.3 (95/155) | 38.7 (60/155) | |
| Ki-67 | 0.127 | ||
| ≤5% | 64.1 (107/167) | 35.9 (60/167) | |
| >5% | 53.5 (38/71) | 46.5 (33/71) | |
| EGFRvIII expression | <0.001 | ||
| Low expression | 77.2 (129/167) | 22.8 (38/167) | |
| High expression | 21.9 (16/73) | 78.1 (57/73) | |